Matt Kane

Matt Kane is a veteran biotechnology company leader with deep experience in advanced genetic medicines. Matt was previously the CEO of leading epigenetic editing company, Tune Therapeutics. While leading Tune, he secured over $100M in financing and positioned the company to enter human clinical studies with a potential functional cure for hepatitis B.

Prior to Tune, Mr. Kane was the co-founder and CEO of Precision BioSciences, a company focused on developing gene and cell therapies using a novel gene editing platform. As CEO of Precision BioSciences, he led a team that raised over $400M in equity and debt financing, including an IPO in 2019, formed partnerships with leading biopharmaceutical companies valued at over $4.7B, and advanced four unique genetic medicines into human clinical trials.

Matt has over twenty years of experience in the life sciences industry and was formerly with Suros Surgical Systems, later acquired by Hologic. He received his B.S. and M.S. from the Rose-Hulman Institute of Technology, and an MBA from Duke University.